These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38751755)

  • 1. Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study.
    Lin J; Li Y; Gui M; Bu B; Li Z
    Ther Adv Neurol Disord; 2024; 17():17562864241251476. PubMed ID: 38751755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis.
    Yin J; Zhao M; Xu X; Zhang M; Xu Z; Li Z; Qin X; Li Z; Zhao C; Zhou H; Ma Y; Cao W; Wang G; Lin Y; Zhang J; Zhang X; Cai H; Qian W; Wang Y; Zhang X; Liu G; Wang J; Qiu W; Min L; Li J; Deng H; Chu L; Zhang Y; Fang J
    Eur J Neurol; 2024 Aug; 31(8):e16322. PubMed ID: 38726639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
    Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
    Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
    Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
    Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod.
    Zhang C; Lin Y; Kuang Q; Li H; Jiang Q; Yang X
    Front Immunol; 2024; 15():1400459. PubMed ID: 38799457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.
    Di L; Shen F; Wen X; Lu Y; Zhu W; Wang M; Da Y
    Front Immunol; 2022; 13():839075. PubMed ID: 35371086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.
    Ruan Z; Tang Y; Gao T; Li C; Guo R; Sun C; Huang X; Li Z; Chang T
    CNS Neurosci Ther; 2024 Jun; 30(6):e14793. PubMed ID: 38894580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in Myasthenia Gravis- Experience from a Low- and Middle-Income Country (LMIC) Setting.
    Shivaram S; Nagappa M; Varghese N; Seshagiri DV; Duble S; Siddappa SA; Hesarur N; Sinha S; Taly AB
    Neurol India; 2022; 70(5):1931-1941. PubMed ID: 36352590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
    Suh J; Clarke V; Amato AA; Guidon AC
    Muscle Nerve; 2022 Sep; 66(3):348-353. PubMed ID: 35684980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study.
    Meng X; Zeng Z; Wang Y; Guo S; Wang C; Wang B; Guo S
    Neuropsychiatr Dis Treat; 2022; 18():953-964. PubMed ID: 35535211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients.
    Wang P; Zhang B; Yin J; Xi J; Tan Y; Gao F; Zeng F; Chang T; Zhou H; Liang H; Zhao Z; Yang H; Zhao C; Huang S
    Front Neurol; 2024; 15():1407418. PubMed ID: 38966082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
    Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
    Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
    Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
    Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.
    Lu J; Zhong H; Jing S; Wang L; Xi J; Lu J; Zhou L; Zhao C
    Muscle Nerve; 2020 Mar; 61(3):311-315. PubMed ID: 31875994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis.
    Jia D; Zhang F; Li H; Shen Y; Jin Z; Shi FD; Zhang C
    Aging Dis; 2024 Apr; 15(2):824-830. PubMed ID: 37450932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different characteristics of nonthymomatous generalized myasthenia gravis with and without oropharyngeal involvement.
    Yu L; Li J; Ma S; Jiang J; Wang T; Gamliel Z; Jing Y; Zhang X; Krasna MJ
    Ann Thorac Surg; 2007 Nov; 84(5):1694-8. PubMed ID: 17954087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
    Wu H; Chen L; Zhou X; Wu Y; Yan Y; Zhu Y; Zhao C; Xue Q
    J Neuroimmunol; 2022 Nov; 372():577955. PubMed ID: 36054935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
    Howard JF; Bril V; Vu T; Karam C; Peric S; De Bleecker JL; Murai H; Meisel A; Beydoun SR; Pasnoor M; Guglietta A; Van Hoorick B; Steeland S; T'joen C; Utsugisawa K; Verschuuren J; Mantegazza R;
    Front Neurol; 2023; 14():1284444. PubMed ID: 38318236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.